Pipeline
PH1 payload is the cornerstone of building an ADC pipeline against wide range of tumors
akaritx.comCrawled Nov 19, 2026
PH1 payload is the cornerstone of building an ADC pipeline against wide range of tumors
The CEO Corner is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.
Akari is developing PAS-nomacopan, a potential treatment requiring four or fewer annual eye injections.
Thrombotic microangiopathy following a stem cell transplant is a rare but serious complication that often leads to progressive organ damage and death. Akari is working with urgency to develop bispecific (C5+LTB4) inhibitor #nomacopan for severe pediatric #HSCT-TMA.
Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, announced the first patient has been enrolled in its Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis.
Combination Synergy of a Spliceosome Modulator ADC with a K-RAS Inhibitor in K-RAS Mutated Pancreatic Cancers 2026 ASCO Annual Meeting
Abizer Gaslightwala, Director, President and CEO
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical product candidates Access the video here
Dr. Hoyoung Huh is the founder of Peak Bio Inc. (f/k/a pH Pharma) and has held positions of Chief Executive Officer and Board Chairman since founding pH Pharma in 2015. He currently serves as a director on the board of directors (the “Board”) of the Company. Dr. Huh is a Silicon Valley-based entrepreneur and investor in healthcare and technology-based businesses and has served as Lead Director of Pliant Therapeutics since December 2017. Dr. Huh was a Managing Director of Konus Advisory Group, In
Dr. Patricia LoRusso has over 25 years of experience in medical oncology and drug development, currently serving as Yale Cancer Center’s Amy and Joseph Perella Professor of Medicine and Chief of Experimental Therapeutics.
Akari Therapeutics develops antibody-drug conjugates (ADCs) with a unique RNA-splicing payload, PH1. Its lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells.
ENGLAND 75/76 Wimpole Street London W1G 9RT, UK +44 (0)20.8004.0261 (phone) info@akaritx.com
AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE